Compare Crispr Therapeutics AG (CRSP) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs SiTime Corporation — how do they compare? Crispr Therapeutics AG trades at $53.04 (market cap $4.88B), while SiTime Corporation trades at $624 (market cap $19.42B). The key difference: SiTime Corporation is far larger — about 4× Crispr Therapeutics AG's market cap, and SiTime Corporation is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and SiTime Corporation for 18 Days on average.
| CRSP | SITM | |
|---|---|---|
Market Cap | $4.88B | $19.42B |
Volume | 2,861,747 | 360,307 |
Sector | Health | Technology |
52-Week High | $74.92 | $901.60 |
52-Week Low | $44.34 | $252.76 |
Typical Hold Time | 77 Days | 18 Days |
Enterprise Value | $3.30B | $18.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
SITM is trading at $665.16, down 6.46% over the past 24 hours, with a bullish technical signal supported by moving averages. The company shows strong revenue growth momentum with Q2 2026 revenue surging 126.5% year-over-year to $157.43 million, marking its first GAAP profit. Analyst consensus remains strongly positive with 9 buy ratings and a $751.43 price target representing 13% upside potential. Recent institutional activity includes California State Teachers Retirement System increasing its stake by 73,098.9% during the latest quarter.
The outlook remains positive driven by AI infrastructure demand and the Renesas acquisition, though valuation metrics appear elevated with P/E at 1,076 and P/S at 36.9. Key risks include execution challenges in scaling operations and potential market volatility. The stock's current position near recent highs suggests cautious optimism is warranted despite strong growth fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
